Abstract Number: 2467 • ACR/ARHP Annual Meeting 2018
RAPID3 Is Elevated in 93% of Treatment-Naïve Rheumatoid Arthritis (RA) Patients at Initial Visit Compared to 49% for Erythrocyte Sedimentation Rate (ESR) and 44% for C-Reactive Protein (CRP)
Background/Purpose: Quantitative measures to assess and monitor patients with rheumatoid arthritis (RA) traditionally have been laboratory tests, such as erythrocyte sedimentation rate (ESR) and C-reactive…Abstract Number: 2031 • ACR/ARHP Annual Meeting 2017
Online Viewing of Labs in RA Patients Is Not Associated with Clinically Significant Change in ESR over 18 Months Compared to Non-Viewers
Background/Purpose: As part of passage of the Affordable Care Act in 2010, Meaningful Use Core Measures were outlined to improve electronic medical record (EMR)…Abstract Number: 491 • ACR/ARHP Annual Meeting 2016
Anti-Citrullinated Peptide Antibodies Testing Rate over Time in Newly Diagnosed RA Patients – Data from Three Administrative Claims Databases (2007–2014)
Background/Purpose: Current clinical guidelines recommend testing for anti-citrullinated protein antibodies (ACPA) at the time of RA diagnosis.1 However, there is a lack of information about…Abstract Number: 2676 • ACR/ARHP Annual Meeting 2015
Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria…Abstract Number: 1519 • ACR/ARHP Annual Meeting 2014
Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI-TNF Drugs
Background/Purpose To evaluate the application of an acid dissociation procedure in monitoring patients with subtherapeutic serum concentrations of infliximab (IFX), adalimumab (ADL) and etanercept (ETN),…
ACR Meeting Abstracts